Risk Score Model for Predicting Mortality Among Patients with Lung Cancer

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Oct 30

PMID 39473493

Authors

Youn Huh

Hae-Rim Kim

Hwa Jung Kim

Ki Young Son

Affiliations

Soon will be listed here.

Abstract

Background: To develop an accurate mortality risk predictive model among patients with lung cancer.

Methods: The development cohort included 96,255 patients with lung cancer aged ≥19 years, who underwent a Korean National Health Insurance Service health check-up from 2005 to 2015. The validation cohort consisted of 18,432 patients (≥19 years) with lung cancer from another region. The outcome was all-cause mortality between January 1, 2005, and December 31, 2020.

Results: Approximately 60.5% of the development cohort died within a median follow-up period of 2.32 (0.72-5.00) years. Risk score was highest in participants aged ≥65 years, followed by those who underwent treatment, had a history of emergency room visits, and were current smokers. Participants treated by surgery had the lowest risk score, followed by combined surgery and chemotherapy, combined surgery and radiation therapy, women, and regular exercisers. The C statistic in the development and validation cohorts was 0.78 (95% confidence interval, 0.77-0.78) and 0.81 (95% confidence interval, 0.78-0.84), respectively.

Conclusion: Advanced age, lung cancer stage, and treatment type were strong risk factors of mortality in lung cancer patients, while being a woman and exercise were preventive factors. These will aid in the prediction of mortality and management of lung cancer patients.

References

Wang J, Xu H, Zhou S, Wang D, Zhu L, Hou J . Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis. Eur J Clin Nutr. 2017; 72(1):4-17. DOI: 10.1038/ejcn.2017.70. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Bandini M, Marchioni M, Pompe R, Tian Z, Martel T, Chun F . The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. Can Urol Assoc J. 2018; 12(7):E325-E330. PMC: 6118051. DOI: 10.5489/cuaj.4854. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Lai C, Ho C, Chen C, Chiang S, Chao C, Liu W . Risk factors and mortality of adults with lung cancer admitted to the intensive care unit. J Thorac Dis. 2018; 10(7):4118-4126. PMC: 6105991. DOI: 10.21037/jtd.2018.06.165. View

Lewis G, Vaithianathan R, Wright L, Brice M, Lovell P, Rankin S . Integrating care for high-risk patients in England using the virtual ward model: lessons in the process of care integration from three case sites. Int J Integr Care. 2013; 13:e046. PMC: 3821539. DOI: 10.5334/ijic.1150. View

Piccirillo J, Tierney R, Costas I, Grove L, Spitznagel Jr E . Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291(20):2441-7. DOI: 10.1001/jama.291.20.2441. View

Soares M, Salluh J, Ferreira C, Luiz R, Spector N, Rocco J . Impact of two different comorbidity measures on the 6-month mortality of critically ill cancer patients. Intensive Care Med. 2005; 31(3):408-15. DOI: 10.1007/s00134-005-2554-z. View

10.

Sauto Arce R, Saenz de Ormijana A, Orueta J, Gagnon M, Nuno-Solinis R . A qualitative study on clinicians' perceptions about the implementation of a population risk stratification tool in primary care practice of the Basque health service. BMC Fam Pract. 2014; 15:150. PMC: 4165939. DOI: 10.1186/1471-2296-15-150. View

11.

Lemke K, Weiner J, Clark J . Development and validation of a model for predicting inpatient hospitalization. Med Care. 2011; 50(2):131-9. DOI: 10.1097/MLR.0b013e3182353ceb. View

12.

Sase K, Fujisaka Y, Shoji M, Mukai M . Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Curr Treat Options Oncol. 2021; 22(8):71. DOI: 10.1007/s11864-021-00869-6. View

13.

van Oostrom S, Picavet H, de Bruin S, Stirbu I, Korevaar J, Schellevis F . Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam Pract. 2014; 15:61. PMC: 4021063. DOI: 10.1186/1471-2296-15-61. View

14.

Sui X, Lee D, Matthews C, Adams S, Hebert J, Church T . Influence of cardiorespiratory fitness on lung cancer mortality. Med Sci Sports Exerc. 2009; 42(5):872-8. PMC: 2859116. DOI: 10.1249/MSS.0b013e3181c47b65. View

15.

Read W, Tierney R, Page N, Costas I, Govindan R, Spitznagel E . Differential prognostic impact of comorbidity. J Clin Oncol. 2004; 22(15):3099-103. DOI: 10.1200/JCO.2004.08.040. View

16.

Donate-Martinez A, Ferrer J, Rodenas Rigla F . Application of screening tools to detect risk of hospital readmission in elderly patients in Valencian Healthcare System (VHS) (Spain). Arch Gerontol Geriatr. 2014; 59(2):408-14. DOI: 10.1016/j.archger.2014.06.004. View

17.

Lee S, Lee J, Park Y, Lee C, Lee S, Yim J . Impact of smoking on mortality of patients with non-small cell lung cancer. Thorac Cancer. 2016; 5(1):43-9. PMC: 4704273. DOI: 10.1111/1759-7714.12051. View

18.

Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M . Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011; 68(4):387-420. DOI: 10.1177/1077558711399580. View

19.

Goodman R, Posner S, Huang E, Parekh A, Koh H . Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013; 10:E66. PMC: 3652713. DOI: 10.5888/pcd10.120239. View

20.

Bunn Jr P, Shepherd F, Sandler A, Le Chevalier T, Belani C, Kosmidis P . Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003; 41 Suppl 1:S175-86. DOI: 10.1016/s0169-5002(03)00161-2. View